The U.S. Food and Drug Administration has approved LANGLARA™ (insulin glargine-aldy), a biosimilar to Lantus® (insulin glargine), offering a potentially more affordable treatment option for patients with diabetes in the United States. The therapy was developed through a collaboration between Lannett Company, Inc., its subsidiary Lanexa Biologics, and Sunshine Lake Pharma.
LANGLARA has been approved for use in adults and pediatric patients with type 1 diabetes, as well as adults with type 2 diabetes. Importantly, the FDA has designated the product as interchangeable with Lantus, meaning pharmacists can substitute it without requiring approval from the prescribing physician, depending on state laws. This designation is expected to play a key role in improving patient access and reducing costs.
The approval follows a comprehensive development program that included analytical, preclinical, and clinical studies. These evaluations demonstrated that LANGLARA matches Lantus in terms of pharmacokinetics, pharmacodynamics, efficacy, safety, and immunogenicity across both type 1 and type 2 diabetes populations.
Industry leaders emphasized that affordability and availability remain major barriers for patients managing diabetes. Tim Crew, CEO of Lannett, noted that the introduction of LANGLARA is intended to expand access to insulin therapy, particularly for patients who struggle with the high cost of treatment. He also highlighted the importance of the interchangeability designation, describing it as a reflection of the scientific rigor behind the product and a key factor in ensuring widespread adoption.
LANGLARA will be manufactured by Sunshine Lake Pharma, part of HEC Group, which has invested heavily in large-scale production capabilities. This manufacturing capacity is expected to support consistent supply, addressing one of the longstanding challenges in the insulin market, where limited manufacturers have constrained availability.
Richard Tang, President of HEC Group, underscored the scale of investment required to bring such a product to market. He stated that the partnership with Lannett and Lanexa Biologics aims to ensure that patients in the U.S. gain timely access to a reliable and cost-effective insulin option.
Lanexa Biologics will handle the exclusive commercialization of LANGLARA in the United States, with plans to secure broad formulary placement across commercial channels. This strategy is expected to further enhance accessibility and encourage adoption among healthcare providers and patients.
The approval of LANGLARA reflects a broader push within the pharmaceutical industry to introduce biosimilars that can reduce healthcare costs while maintaining high standards of safety and efficacy. For millions of people living with diabetes, the availability of interchangeable insulin products could represent a meaningful step toward more affordable and accessible care.